Drug intelligence / Profile preview

YJF-009

Development stage: Preclinical
Lead developer: Hanwha Pharma
Modality: Small Molecules

Overview

YJF-009 is a generic drug candidate currently in the preclinical research and formulation stage, developed by Han Wha Pharma. It is part of the company's respiratory pipeline, aimed at treating various respiratory system disorders. As a generic candidate, YJF-009 is being developed to be a bioequivalent version of an existing, off-patent pharmaceutical product. While the specific reference molecule and target mechanism have not been publicly disclosed, the drug is categorized within Han Wha's generic development program alongside other respiratory candidates like YJF-015 and YJF-019.

Beyond the preview

Go deeper on YJF-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YJF-009.

Explore the full profile